Bossen L, et al. - Utilizing data from three randomized trials of satavaptan in cirrhosis patients with ascites, researchers investigated the connection between serum sodium, changes in serum sodium, and hepatic encephalopathy (HE) incidence. Patients were examined for HE during follow-up, and serum sodium was regularly assessed. There were 1,116 patients, 302 of whom had HE. Data reported that, at inclusion, median serum sodium was 137. For each decrease in serum sodium mmol/L, data results showed HE development hazard rates increased by 8%. In addition, current serum sodium had a stronger HE-rate impact than serum sodium changes.